1. Medtech Insight
  2. >>Business
  3. >>Strategy

LivaNova Sells Surgical Heart Valve Business To Gyrus Capital For $73M

 
• By Reed Miller

Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.

Investing in new business while divesting in old industry with an old tree shaped as a finance pie chart graph funding a green tree
• Source: shutterstock.com

LivaNova PLC is selling its surgical heart valve business to Swiss private equity firm Gyrus Capital for €60m ($73m), the companies announced on 3 December.

LivaNova’s heart valve business includes the Perceval sutureless aortic valve, along with the Solo Smart aortic pericardial tissue valve with a removable stent, and the Carbomedics line of mechanical aortic prostheses

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By Shubham Singh

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

More from Business

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.